Tenofovir alafenamide in chronic hepatitis B: Added benefit not proven, data incomplete
The antiviral drug tenofovir alafenamide (TAF) has been used since 2015 in different combinations for the treatment of HIV and has already been subject to 3 early benefit assessments for this therapeutic indication. It has ...
Jul 5, 2017
0
0